“We strongly believe that we have reasons to disagree with the claim that they have made. Fundamentally, we also believe that the patent invalidated is something that we will continue to fight for, Uday Baldota, vice president - investor relations, Sun Pharma told CNBC-TV18.
first published: Feb 16, 2012 11:35 am
A collection of the most-viewed Moneycontrol videos.
Live: Nifty extends gain for the third day, up nearly 2% this week | Closing Bell | 4K
From renewables to AI and SMEs: Madhusudan Kela on where he senses opportunity now
Will The Pre-Diwali Nifty Rally Rage On Amid Weak Global Cues? RIL Q2 in Focus | Opening Bell Live
Infosys Q2 Earnings Live | Decoding Infosys Q2 Earnings | Earnings Express
